Evidence map›Paper›PMID 42236852›Full record

ArticleScientific reports2026

The predictive value of systemic inflammation response index and albumin-to-globulin ratio for prognosis in non-small cell lung cancer.

Qiuping Xu, Yinyin Deng, Yuping Cai, Shaobin Yu, Mingqiang Kang, Fei He

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiuping XuMedical Department, The Affiliated Hospital of Putian University, Putian, Fujian, China.
Yinyin DengDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, 350122, Fujian, China.
Yuping CaiMedical Department, The Affiliated Hospital of Putian University, Putian, Fujian, China.
Shaobin YuFujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Mingqiang KangFujian Medical University Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Fei HeDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, 350122, Fujian, China. i.fei.he@fjmu.edu.cn.

Funding

Fujian Provincial Natural Science Foundation Project 2023J01093
6 · The paper itself

Abstract

We investigated whether inflammatory markers would be significant prognostic factors for survival in patients with non-small-cell lung cancer (NSCLC). This was a retrospective cohort study including 748 consecutive Chinese NSCLC patients. The relationships of inflammatory markers with clinicopathologic characteristics and prognosis were analyzed by chi-squared test and Cox regression. Restricted cubic splines (RCS) with 4 knots were used to flexibly model non-linear relationships between markers and overall survival (OS). Survival was estimated using Kaplan-Meier curves. In multivariate analysis, the systemic inflammation response index (SIRI) and albumin-to-globulin ratio (AGR) were independently associated with OS (HR: 1.506, 95% CI: 1.224-1.852; HR: 0.749, 95% CI: 0.608-0.923). RCS showed a non-linear association for SIRI (P for non-linear = 0.004) and a linear association for AGR (P for non-linear = 0.258). We constructed a 3-tier SIRI-AGR score: Score 1 (low risk: SIRI ≤ 0.91 and AGR > 1.19), Score 2 (intermediate: either SIRI > 0.91 or AGR ≤ 1.19, but not both), Score 3 (high risk: SIRI > 0.91 and AGR ≤ 1.19). Patients with Score 3 had significantly shorter OS (HR: 1.974; 95% CI: 1.486-2.622). Time-dependent ROC showed stable predictive performance with AUC ≈ 0.70 throughout follow-up. The SIRI-AGR score is an independent, convenient, and low-cost prognostic factor for NSCLC. It can serve as a useful indicator for risk stratification and clinical decision-making.

Indexed as

Carcinoma, Non-Small-Cell LungGlobulinsLung NeoplasmsSerum AlbuminSerum GlobulinsAgedBiomarkers, TumorFemaleHumansInflammationKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesROC CurveBiomarkers, TumorGlobulinsSerum AlbuminSerum GlobulinsAlbumin-to-globulin ratioNon-small-cell lung cancerOverall survivalSystemic inflammation response index

Identifiers

PMID42236852
PMCPMC13473555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.